These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 2316048)

  • 1. [Ketanserin. A new antihypertensive agent with an antagonistic effect on serotonin].
    Kristensen KS; Jensen HA; Svendsen TL
    Ugeskr Laeger; 1990 Mar; 152(12):837-8. PubMed ID: 2316048
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of ketanserin in anesthesia. A selective S2 serotonin receptor antagonist].
    Nielsen LH; Knudsen F; Olesen AS
    Ugeskr Laeger; 1990 Jun; 152(23):1653-5. PubMed ID: 2194327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
    Prostran M
    Srp Arh Celok Lek; 1994; 122(3-4):99-102. PubMed ID: 17972821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of pharmacologic blockade of serotonin receptors (S2) on arterial pressure in rats with 2 forms of hereditary arterial hypertension].
    Popova NK; Piianzin AI; Markel' AL
    Farmakol Toksikol; 1989; 52(6):58-61. PubMed ID: 2516487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of action and use of antagonists of serotonin receptors S2, especially ketanserin, in the treatment of various diseases of the cardiovascular system].
    Wiecek A; Grzeszczak W
    Pol Tyg Lek; 1987 Mar; 42(10):304-8. PubMed ID: 3299308
    [No Abstract]   [Full Text] [Related]  

  • 7. [Serotonin antagonists for the treatment of hypertension].
    Bühler FR
    Schweiz Med Wochenschr; 1988 Sep; 118(36):1259-60. PubMed ID: 3175572
    [No Abstract]   [Full Text] [Related]  

  • 8. Serotonin agonists and antagonists in experimental hypertension.
    Saxena PR; Bolt GR; Dhasmana KM
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S12-8. PubMed ID: 2446059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rationale for ketanserin therapy in hypertension.
    Hansson L; Hedner T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S39-44. PubMed ID: 2446068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B; Gradin K; Pettersson A; Hedner T
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketanserin for hypertension after upper gastrointestinal surgery.
    Bogle RG
    Lancet; 1991 May; 337(8751):1219-20. PubMed ID: 1673753
    [No Abstract]   [Full Text] [Related]  

  • 13. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors.
    Shen FM; Wang J; Ni CR; Yu JG; Wang WZ; Su DF
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):702-7. PubMed ID: 17600544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced anti-platelet effect.
    De Clerck F
    Thromb Haemost; 1986 Oct; 56(2):236. PubMed ID: 3810559
    [No Abstract]   [Full Text] [Related]  

  • 15. The inhibitory effect of interferon-alpha on the serotonin-induced impairment of human NK cell activity in whole blood.
    Garssadi SI; Mándi Y; Régely K; Taródi B; Béládi I
    Brain Behav Immun; 1993 Jun; 7(2):164-75. PubMed ID: 8347897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal hemodynamic effects of ketanserin therapy in essential hypertension.
    Ram CV; Gonzalez DG; Kaplan NM; Ralakis JM; Henderson JD; Lugo CE; Zachariah N
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S78-80. PubMed ID: 2446078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of serotonin and its receptors in the pathogenesis of arterial hypertension].
    Belousov IuB; Krivonkin KIu
    Kardiologiia; 1992; 32(11-12):5-9. PubMed ID: 1297881
    [No Abstract]   [Full Text] [Related]  

  • 18. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ; Reneman RS
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin.
    Frishman WH; Okin S; Huberfeld S
    Med Clin North Am; 1988 Mar; 72(2):501-22. PubMed ID: 3279288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
    Ikeda K; Takata M; Tomoda F; Mikawa M; Iida H; Sasayama S
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S69-72. PubMed ID: 2446076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.